Ultimovacs is a norwegian clinical phase biotech with a universal cancer vaccine as its lead product.
Today the company reported to the market that in march it will share topline data from its randomized phase 2 trial INITIUM for its lead product UV1 , a universal cancer vaccine to be used in combination with checkpoint inhibitors.
The stock is at the...
Ultimovacs’ UV1 in combination with pembrolizumab shows 60% Objective Response Rate in advanced melanoma Phase I data
• UV1/pembrolizumab results in 30% complete responses plus 30% partial responses
• Good safety and tolerability profile supports use of UV1 in combination treatments
• Data to be presented at ASCO and abstract to be discussed in webcast on May...
Note that information about the third study is still expected before year end.
Ultimovacs ASA – Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab
Oslo, 22 December 2020: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), today announced the initiation of FOCUS, a Phase II randomized clinical...
Oslo, 19 October 2020: Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today
announced five-year overall survival data from the Phase I trial evaluating UV1
as maintenance therapy in patients with non-small cell lung cancer. The results
confirm achievement of the primary endpoints of safety and tolerability and
indicate encouraging initial signals of long-term...
